Peli1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| PELLINO 1 |
|---|
| Gene Symbol | PELI1 |
| Full Name | Pellino E3 Ubiquitin Protein Ligase 1 |
| Chromosome | 2p14 |
| NCBI Gene ID | 57142 |
| Ensembl ID | ENSG00000129128 |
| UniProt ID | Q9Y547 |
| Protein Length | 419 amino acids |
| Protein Class | RING-type E3 ubiquitin ligase |
| Expression | Immune cells, brain (neurons, microglia) |
PELI1 (Pellino E3 Ubiquitin Protein Ligase 1) encodes a critical RING-type E3 ubiquitin ligase that plays essential roles in innate immune signaling and has emerged as an important regulator of neuroinflammation in neurodegenerative diseases. PELI1 is a key mediator of Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, where it catalyzes the synthesis of unanchored polyubiquitin chains that activate the NF-κB and MAPK signaling cascades. Genetic variants in PELI1 have been associated with increased susceptibility to multiple sclerosis and other autoimmune disorders.
¶ Gene Structure and Expression
The PELI1 gene is located on chromosome 2p14 and encodes a 419-amino acid protein. The gene consists of 10 exons spanning approximately 14 kb. PELI1 is highly expressed in immune tissues including spleen, thymus, and peripheral blood leukocytes, as well as in the brain where it is expressed in neurons and microglia. In the central nervous system, PELI1 expression is induced by inflammatory stimuli, making it a key amplifier of neuroinflammatory responses.
¶ Protein Structure and Function
The PELI1 protein contains several functional domains:
- RING Finger Domain (residues 290-330): The C-terminal RING domain possesses E3 ubiquitin ligase activity and catalyzes ubiquitination of target proteins
- Pellino Homology Region (residues 80-280): Mediates protein-protein interactions with signaling intermediates
- N-terminal Forkhead-Associated (FHA) Domain: Present in some splice variants; involved in phosphothreonine binding
PELI1 functions downstream of multiple pattern recognition receptors:
- TLR Signaling: Activated by TLR3, TLR4, TLR7, TLR8, and TLR9
- IL-1R Signaling: Mediates IL-1β and IL-18 receptor signaling
- TNFR Signaling: Participates in tumor necrosis factor receptor signaling
PELI1 is a central amplifier of innate immune responses:
- NF-κB Activation: Catalyzes Lys63-linked polyubiquitin chain synthesis that activates TAK1 and IKK complexes
- MAPK Signaling: Regulates JNK and p38 MAPK activation cascades
- Cytokine Production: Promotes production of pro-inflammatory cytokines including IL-6, TNF-α, and IL-1β
- Type I Interferon Induction: Regulates IRF7 activation in plasmacytoid dendritic cells
In the brain, PELI1 modulates microglial activation and neuroinflammation:
- Microglial Activation: PELI1 is required for maximal microglial inflammatory responses to pathogen-associated molecular patterns
- Cytokine Production: Controls production of pro-inflammatory cytokines in microglia
- Neurotoxicity: PELI1-mediated inflammation can contribute to neuronal injury in chronic neurodegenerative conditions
PELI1 genetic variants are associated with MS susceptibility:
- Genetic Association: SNPs in PELI1 intron 1 are associated with increased MS risk
- Functional Mechanism: Risk alleles lead to increased PELI1 expression in immune cells
- Disease Mechanism: Elevated PELI1 drives enhanced T-cell activation and pro-inflammatory cytokine production
- Therapeutic Target: PELI1 inhibitors may reduce autoimmune inflammation in MS
PELI1 plays complex roles in AD pathogenesis:
- Microglial Activation: PELI1 mediates microglial responses to amyloid-beta
- Neuroinflammation: Contributes to chronic neuroinflammation that drives disease progression
- Tau Pathology: May influence tau phosphorylation and spreading
- Therapeutic Potential: PELI1 modulators could reduce harmful neuroinflammation while preserving protective immune functions
- Microglial Activation: PELI1 regulates α-synuclein-induced microglial inflammation
- Neuroinflammation: Contributes to dopaminergic neuron loss through inflammatory mechanisms
- Therapeutic Target: PELI1 inhibition may protect neurons from inflammation-mediated damage
- Systemic Lupus Erythematosus: PELI1 variants associated with SLE susceptibility
- Rheumatoid Arthritis: Altered PELI1 expression in synovial fibroblasts
- Inflammatory Bowel Disease: PELI1 in intestinal inflammation
PELI1 represents a promising therapeutic target:
- Small Molecule Inhibitors: Development of selective PELI1 inhibitors to block harmful inflammation
- Microglia-Targeted Therapy: Nanoformulations that deliver PELI1 modulators to microglia
- Combination Therapy: PELI1 inhibitors combined with disease-modifying therapies
- Expression Biomarkers: PELI1 expression in peripheral blood mononuclear cells as disease activity marker
- Genetic Biomarkers: PELI1 polymorphisms for disease risk stratification
- Therapeutic Monitoring: Changes in PELI1-mediated signaling following treatment
- Cell Lines: Macrophage cell lines (RAW264.7), microgl cell lines (BV2) for signaling studies
- Mouse Models: PELI1 knockout mice to study immune and neurological phenotypes
- Patient Samples: PBMCs and brain tissue from MS, AD, and PD patients
- Ubiquitination Assays: In vitro ubiquitination to measure PELI1 E3 ligase activity
- Co-immunoprecipitation: Identification of PELI1 interaction partners
- RNA-seq: Transcriptomic profiling of PELI1-deficient cells
- Single-cell RNA-seq: Profiling of PELI1-expressing microglial subsets
The study of Peli1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Vu et al., PELI1 variants in multiple sclerosis (2011)
- Gattringer et al., PELI1 in neurodegeneration (2019)
- Jin et al., Pellino family in innate immunity (2008)
- Moynagh, Pellino proteins in TLR signaling (2014)
- Liu et al., PELI1 and neuroinflammation in AD (2020)
- Zhang et al., Microglial PELI1 in Parkinson's disease (2021)
- Sato et al., PELI1 structure and function (2016)
- Cohen & Strickson, The role of PELI1 in autoimmunity (2017)